IBRX Immunitybio Inc
Company Analysis
Latest News
🟢 Immunitybio is trading 6.1% up today as in-line August CPI eases inflation concerns
Immunitybio is trading at $8.19, up +6.09%, alongside a broad market rally after August CPI showed 3.4% annual inflation, matching forecasts and easing...
🔴 Immunitybio is trading 4.03% down today as producer inflation pressures rate-cut expectations
Immunitybio is trading $7.74 (-4.03%) amid broad risk-off trading as hotter producer inflation pressures rate-cut expectations. • S&P 500, Nasdaq, and Dow are...
🔴 Immunitybio is trading 4.3% down today amid surging oil prices and U.S.-Iran tensions
Immunitybio is trading 4.3% down at $7.93 amid broader market weakness and heightened geopolitical risk. - The Nasdaq and Dow are each down more than 0.5%,...
🟢 Immunitybio is trading 4.57% up today with no new company-specific catalyst identified
Immunitybio is trading 4.57% up at $8.23; no new company-specific announcement dated September 2, 2026 was identified. - The latest listed releases concern...
🔴 Immunitybio is trading 4.52% down today amid biotech weakness on Fed rate uncertainty
Immunitybio is trading 4.52% down now at $8.02 as biotechnology stocks weaken amid rate uncertainty surrounding Federal Reserve Chair Kevin Warsh’s Jackson...
🟢 Immunitybio is trading 4.5% up today as U.S. equities advance
Immunitybio is trading 4.54% up now at $8.62 as U.S. equities advance. - The Nasdaq Composite is up 1.38%, while the S&P 500 is up 0.64%. - No fresh...
🟢 Immunitybio is trading 4.16% up today as XBI rises 2.06%
Immunitybio is trading 4.16% up at $7.89, with biotech-sector strength appearing to provide the main tailwind as XBI gains 2.06%. - No new company-specific...
🔴 Immunitybio is trading 4.37% down today as broader biotech weakness reverses sector rally
Immunitybio is trading 4.37% down now at $7.78 after broader biotech weakness reversed the sector’s previous-session rally. - No fresh company-specific...
🟢 Immunitybio is trading 5.6% up today on biotech-sector strength
Immunitybio is trading at $8.15, up 5.63%, as strength across the biotechnology sector lifts sentiment. - XBI is up 3.73% during regular trading after...
🟢 Immunitybio is trading 4.4% up in pre-market as biotech ETF XBI rises 2.27%
Immunitybio is trading at $8.06 (+4.40%), primarily on biotech-sector strength. - Biotech ETF XBI is up 2.27% pre-market after positive Merck-Moderna...
🔴 Immunitybio is trading 4.42% down today as U.S. markets weaken
Immunitybio is trading 4.42% down now at $7.57 as U.S. markets weaken. - The S&P 500 is down 0.58%, while the Nasdaq Composite is down 1.36%. - The broader...
Goldman Sachs Holds $28M ImmunityBio Stake, Eyeing Cancer Drug Catalysts
Goldman Sachs disclosed a $28.32 million holding in ImmunityBio. The position includes 3.23 million shares. This holding remained nearly unchanged from the...
🟢 Immunitybio is trading 4.03% up today with no clear company-specific catalyst
Immunitybio is trading 4.03% up at $7.88, with no clear company-specific catalyst identified for August 17, 2026. - Its investor-relations page lists the...
ImmunityBio Appoints Former World Bank President Jim Yong Kim, Targeting Global Expansion
ImmunityBio appointed Dr. Jim Yong Kim as Vice Chairman. Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. He will focus on...
🟢 Immunitybio is trading 4.3% up today after Q2 revenue surges 92% YoY
Immunitybio is trading at $7.25 (+4.32%) after reporting second-quarter product revenue of $50.7 million, representing a 92% year-over-year increase. • The...
🔴 Immunitybio is trading 5.2% down today as wider Q2 net loss offsets strong ANKTIVA revenue growth
Immunitybio is trading 5.2% down now at $6.76 after releasing Q2 earnings that showed a wider GAAP net loss per share, primarily driven by non-cash fair value...
ImmunityBio's second quarter product revenue of $50.7M surges 92%, easily beating estimates, while net loss widens.
ImmunityBio reported second quarter 2026 net product revenue of $50.7 million, a 92% increase year-over-year, marking the eighth consecutive quarter of...
Immunitybio Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
ImmunityBio is expected to report a Q2 2026 loss of $0.09 per share on revenue of $18.50 million, while the current stock price of $7.45 remains significantly...
🔴 Immunitybio is trading 4.4% down today amid broader biotech sector weakness
Immunitybio is trading at $7.12 (-4.43%) as the stock pulls back from its recent rally, tracking broader weakness across the biotechnology sector. • The...
ImmunityBio's ANKTIVA® Receives UAE Marketing Authorization for Bladder and Lung Cancer
ImmunityBio announced it has received marketing authorization from the United Arab Emirates (UAE) Emirates Drug Establishment (EDE) for its drug ANKTIVA® for...